GlassScriptPhysician profile
Christopher D Campbell
NPI 1902872351
$2,441.57
in general payments reported to CMS, 2019-2025
29 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $233 · 2021: $280 · 2022: $244 · 2023: $361 · 2024: $343 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $418.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $268.91 | 2019-2021 | |
| Pfizer INC. | $264.78 | 2019-2024 | |
| Glaxosmithkline, LLC. | $188.07 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $186.63 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $145.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $121.96 | 2019-2021 | |
| Lilly USA, LLC | $103.77 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Axsome Therapeutics, INC. | $79.40 | 2024-2025 | Auvelity, Symbravo |
| Exact Sciences Corporation | $63.70 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $62.91 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $61.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.36 | 2019-2024 | Xifaxan |
| Viatris Specialty LLC | $49.17 | 2025 | Yupelri |
| Abbvie INC. | $46.24 | 2021-2023 | Ubrelvy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.78 | 2019 | |
| Irhythm Technologies, INC. | $36.02 | 2019-2020 | |
| Neurelis, INC. | $34.57 | 2023 | Valtoco |
| Mylan Specialty L.P. | $29.69 | 2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $29.06 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.72 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $24.91 | 2022 | |
| Sumitomo Pharma America, INC. | $17.50 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $16.90 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $16.31 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $15.75 | 2021 | |
| Allergan, INC. | $13.17 | 2020 | |
| Abbott Laboratories | $12.87 | 2021 | |
| Merck Sharp & Dohme LLC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.